Millions of people around the world live with type 2 diabetes. This condition happens when the body cannot properly control the level of sugar in the blood. Over time, high blood sugar can damage many parts of the body, including the heart, kidneys, nerves, and eyes. Because of these risks, doctors often prescribe medications to help patients keep their blood sugar under control.
In recent years, a newer group of diabetes drugs called SGLT2 inhibitors has become very popular. These medicines help lower blood sugar in a different way from many older treatments.
Instead of changing how the body uses insulin, they help the kidneys remove extra sugar from the body through urine. This method has worked well for many patients and has helped many people manage their diabetes more effectively.
However, new research has raised concerns about a possible serious side effect linked to these drugs. A study conducted by the U.S. Food and Drug Administration, commonly known as the FDA, has found a possible connection between SGLT2 inhibitors and a rare but dangerous infection called Fournier gangrene. The study was published in the medical journal Annals of Internal Medicine.
Fournier gangrene is a severe infection that affects the tissue around the genital and anal areas. Although it is very rare, it can spread quickly and become life-threatening if it is not treated immediately. The infection destroys tissue and often requires emergency surgery and strong antibiotics. In some cases, patients may need several operations to remove damaged tissue.
Because the infection is so serious, doctors and researchers closely monitor any signs that medications might increase the risk.
The FDA researchers examined reports from patients who had been taking SGLT2 inhibitors. They reviewed medical records and safety reports collected between March 2013 and January 2019. During this period, they identified 55 cases of Fournier gangrene among people using these diabetes medications.
The patients ranged in age from 33 to 87 years old. Among them were 39 men and 16 women. The infection did not appear at the same time for everyone. Some patients developed symptoms only five days after starting the medication. Others did not develop the infection until more than four years after beginning treatment.
Many of these patients were already dealing with serious health problems related to diabetes. Some experienced diabetic ketoacidosis, which is a dangerous condition caused by very high levels of acid in the blood. Others developed sepsis, a severe reaction to infection that can damage organs. Some patients also suffered kidney injury. These additional health problems made their situations more complicated and harder for doctors to treat.
To better understand whether the risk was unusual, the FDA compared these cases with reports linked to other diabetes medications. These included commonly used drugs such as metformin, insulin, and several older treatments.
The researchers looked at a much longer time period for these older drugs, from 1984 to January 2019. During those decades, they found only 19 reported cases of Fournier gangrene among patients using those other medications.
This difference caught the attention of health experts. Even though the infection is still extremely rare, the higher number of cases among people using SGLT2 inhibitors suggests there may be a link between the drugs and the infection.
Because of these findings, the FDA has advised doctors to be especially careful when prescribing these medications. Health professionals are encouraged to monitor patients closely after they begin treatment, especially during the first weeks or months. Watching for early warning signs may help doctors detect infections before they become severe.
Patients who take SGLT2 inhibitors should also be aware of possible symptoms. Pain, swelling, redness, or tenderness in the genital or anal area may be warning signs. Fever or feeling generally unwell may also appear. If any unusual symptoms occur, medical help should be sought immediately.
Despite these concerns, doctors emphasize that SGLT2 inhibitors still offer important benefits for many patients. These medications can improve blood sugar control and may also help protect the heart and kidneys in some people with diabetes. For many patients, these benefits remain very important.
The key message from the research is not that patients should stop their medications on their own. Instead, it highlights the importance of careful monitoring and open communication between patients and healthcare providers.
The study also shows why continued safety monitoring is essential for modern medicines. Even after a drug is approved and widely used, scientists and regulators continue studying its long-term effects. This ongoing research helps ensure that treatments remain as safe as possible for the millions of people who depend on them.
For people living with diabetes, staying informed about medications is an important part of protecting overall health. Understanding both the benefits and the possible risks allows patients and doctors to make the best decisions together.
The FDA study, published in Annals of Internal Medicine, serves as a reminder that even highly effective treatments must be watched carefully. By recognizing warning signs early and maintaining regular medical care, patients can continue managing diabetes while reducing the risk of serious complications.
If you care about diabetes, please read studies about bananas and diabetes, and honey could help control blood sugar.
For more health information, please see recent studies about Vitamin D that may reduce dangerous complications in diabetes and results showing plant-based protein foods may help reverse type 2 diabetes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
